RxDoctor Payments Data

Karla Quevedo, MD

Cardiovascular Disease · Fort Myers, FLNPI 1720218530

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 26 payments — averaging $60.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$892
  • Boehringer Ingelheim$218
  • Medtronic$140
  • Johnson & Johnson$105
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$69
  • Pfizer$52
  • plus $85 from 3 others

What the payments were for

  • Travel & lodging$74448%
  • Food & beverage$81852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$370,833
Medicare patients
2,054
Services billed
6,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban264$400,228
XareltoRivaroxaban124$167,859
JardianceEmpagliflozin72$82,910
EntrestoSacubitril/Valsartan45$64,701
Praluent PenAlirocumab56$48,681
Repatha SureclickEvolocumab26$21,400
Metoprolol Succinate414$5,782
Dofetilide21$4,854
Flecainide Acetate51$3,057
Amiodarone Hcl102$2,803
Atorvastatin Calcium270$2,547
Losartan Potassium214$2,396
Ranolazine ErRanolazine19$2,060
Amlodipine Besylate298$1,617
Rosuvastatin Calcium131$1,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$400,228264 claims
Johnson & JohnsonXarelto$105$167,859124 claims
Boehringer IngelheimJardiance$218$82,91072 claims
NovartisEntresto$25$64,70145 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →